Shire is poised to enter the regenerative medicine market by acquiring Advanced BioHealing (ABH), a US developer of cell-based therapies, for US$750 M in cash. The acquisition was announced the day before ABH was expected to launch an IPO. With the purchase, Shire will gain access to Dermagraft®, a regenerative, bioengineered skin substitute for diabetic foot ulcers that will form the foundation of Shire’s new regenerative medicine unit.